
GOSS Stock Forecast & Price Target
GOSS Analyst Ratings
Bulls say
Gossamer Bio is downgraded due to the recent failure of their PROSERA trial, which fell short of expectations and has raised concerns about the company's ability to find a registrational path for their drug Seralutinib. The company's financials also suffer from high levels of convertible debt and the need for additional financings, which may hinder their progress in bringing their pipeline products to market. Despite the potential upside in addressing diseases such as PH-ILD, the overall execution and confidence in the company's management has been called into question.
Bears say
Gossamer Bio is facing multiple challenges, including underwhelming data and regulatory uncertainty for its lead product Seralutinib in the PAH market. The company's financials are also a cause for concern as they have a significant amount of debt and will likely need additional financing to reach commercialization. As a result, a downgrade to Neutral is justified due to these fundamental issues.
This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GOSS Analyst Forecast & Price Prediction
Start investing in GOSS
Order type
Buy in
Order amount
Est. shares
0 shares